HILE(SH:603718) Bei Jing Shang Bao·2026-02-02 02:16Core Viewpoint - Haili Biological experienced a significant stock decline, hitting the daily limit down of 10.02% to 5.84 CNY per share following the release of its 2025 performance forecast, which indicates potential delisting risk due to expected financial underperformance [1] Financial Performance Summary - The company forecasts a net profit attributable to shareholders for 2025 between 11 million to 16 million CNY, with a non-recurring net profit expected to be between -390 million to -400 million CNY [1] - Expected operating revenue for 2025 is projected to be between 190 million to 195 million CNY, which is below the 300 million CNY threshold [1] Stock Market Response - Following the announcement, Haili Biological's stock price fell to the limit down, reflecting investor concerns regarding the company's financial outlook and potential delisting risk as per the Shanghai Stock Exchange regulations [1] Management Actions - In response to the situation, the company's general manager, Han Benyi, announced plans to voluntarily increase his stake in the company, committing to invest between 1.5 million to 2 million CNY over the next six months to bolster investor confidence [1]